CDTX — Cidara Therapeutics, Inc. Stock Price, Chart & AI Report

Neutral Dec 9, 2025 • 16:15 UTC The Motley Fool • Prosper Junior Bakiny

Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump

Merck's stock rose after positive clinical trial results for Winrevair, a pulmonary hypertension drug acquired through the Acceleron Pharmaceuticals acquisition. The company is strategically preparing for the Keytruda patent expiration in 2028 by developing new drugs and potential treatment expansions.

MRK CDTX pharmaceutical clinical trials acquisition pulmonary hypertension patent cliff

Sentiment note

Recently acquired by Merck with potential for future development

Neutral Dec 7, 2025 • 12:15 UTC The Motley Fool • James Brumley

Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?

Merck's stock has experienced significant volatility, dropping from $130 to $76 and rebounding to around $100. Despite concerns about Keytruda's patent expiration in 2028, the company shows potential through new drug developments, acquisitions, and a promising pharmaceutical pipeline.

MRK CDTX pharmaceutical Keytruda patent expiration drug development healthcare

Sentiment note

Announced acquisition by Merck for over $9 billion, bringing a new flu vaccine candidate into Merck's portfolio

Positive Dec 5, 2025 • 17:05 UTC The Motley Fool • Prosper Junior Bakiny

Is This Pharmaceutical Giant a Buy After a Major Acquisition?

Merck acquired Cidara Therapeutics for $9.2 billion to develop a promising long-acting antiviral drug for influenza, addressing concerns about its post-Keytruda future and expanding its product portfolio with potential blockbuster treatments.

MRK CDTX PFE pharmaceutical acquisition influenza vaccine antiviral

Sentiment note

Attractive acquisition target with promising CD388 flu treatment that could revolutionize influenza prevention

Neutral Nov 27, 2025 • 23:52 UTC GlobeNewswire Inc. • Halper Sadeh Llc

Halper Sadeh LLC Encourages AXTA, SEMR, CDTX Shareholders to Contact the Firm to Discuss Their Rights

Law firm Halper Sadeh LLC is investigating potential securities law violations and breaches of fiduciary duties for three companies involved in recent merger and acquisition transactions.

AXTA SEMR CDTX securities law mergers acquisitions shareholder rights

Sentiment note

Being acquired by Merck for a specific cash price, potential investigation suggests possible examination of transaction fairness

Neutral Nov 27, 2025 • 23:14 UTC GlobeNewswire Inc. • Juan Monteverde

HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN

Law firm Monteverde & Associates is investigating potential merger deals for four companies, examining whether shareholders are receiving fair compensation in recent acquisition transactions.

EXAS SEE CDTX MRSN mergers acquisitions shareholder investigation class action

Sentiment note

Proposed sale to Merck Sharp & Dohme at $221.50 per share requires investigation to determine fairness

Neutral Nov 22, 2025 • 11:03 UTC GlobeNewswire Inc. • Halper Sadeh Llc

Halper Sadeh LLC Encourages THS, CDTX, SPNS Shareholders to Contact the Firm to Discuss Their Rights

Law firm investigating potential securities law violations and fiduciary duty breaches for several companies involved in recent merger and acquisition transactions.

THS CDTX SPNS securities law mergers acquisitions shareholder rights

Sentiment note

Being investigated for potential sale transaction details, no clear indication of wrongdoing

Neutral Nov 21, 2025 • 15:48 UTC Benzinga • Vandana Singh

Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains

Pfizer's Phase 3 study reveals a new nucleoside-modified mRNA influenza vaccine with 34.5% relative efficacy against flu strains, showing superior protection compared to traditional vaccines, though with higher short-term side effects.

PFE MRK CDTX mRNA flu vaccine clinical trial influenza vaccination

Sentiment note

Briefly mentioned as being acquired by Merck, with no direct relation to the vaccine research

Neutral Nov 14, 2025 • 22:30 UTC GlobeNewswire Inc. • Juan Monteverde

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)

Law firm Monteverde & Associates is investigating the proposed sale of Cidara Therapeutics to Merck Sharp & Dohme, where shareholders will receive $221.50 per share in cash.

CDTX merger acquisition shareholder investigation class action

Sentiment note

The investigation suggests potential concerns about the fairness of the merger price, but no definitive negative or positive conclusion is stated

Positive Oct 10, 2025 • 14:55 UTC Benzinga • Evette Mitkov

Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage

Cidara Therapeutics announced a presentation at the ESWI 2025 conference, highlighting translational efficacy data for CD388, its long-acting antiviral drug for influenza prevention. JP Morgan initiated coverage with an Overweight rating and $200 price target, boosting market sentiment.

CDTX influenza antiviral clinical trials drug development biotech

Sentiment note

Positive Phase 2b trial results, FDA Fast Track Designation, JP Morgan Overweight rating, and stock price increase indicate strong market confidence in the company's drug development progress

Positive Oct 9, 2025 • 22:32 UTC The Motley Fool • Eric Volkman

Why Cidara Therapeutics Stock Crushed It Today

Cidara Therapeutics received FDA Breakthrough Therapy designation for its investigational non-vaccine flu drug CD388, which aims to prevent seasonal flu for patients unable or unwilling to take traditional vaccines. The announcement boosted the company's stock price by over 12%.

CDTX Cidara FDA Breakthrough Therapy flu drug CD388

Sentiment note

Stock price increased by 12% after receiving FDA Breakthrough Therapy designation, indicating positive market reaction to potential drug approval and future prospects

Neutral Jul 1, 2025 • 20:59 UTC GlobeNewswire Inc. • Cidara Therapeutics

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cidara Therapeutics granted non-qualified stock options and restricted stock units totaling 12,100 shares to two new employees under its 2020 Inducement Incentive Plan, with stock options priced at $48.71 per share and vesting over four years.

CDTX stock options RSUs biotechnology employee compensation

Sentiment note

Standard routine stock option grant for new employees with typical vesting schedules, indicating normal business operations without significant positive or negative implications

Positive Jun 25, 2025 • 00:00 UTC Benzinga • Globe Newswire

Cidara Announces Pricing of Upsized Public Offering of Common Stock

Cidara Therapeutics announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price of $44.00 per share, raising $350 million in gross proceeds.

CDTX Cidara Therapeutics public offering common stock

Sentiment note

The company is raising a significant amount of capital through a public offering, which suggests it has growth plans and confidence in its business prospects.